1. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Issue 5 (May 2019) Authors: Fizazi, Karim; Tran, NamPhuong; Fein, Luis; Matsubara, Nobuaki; Rodriguez-Antolin, Alfredo; Alekseev, Boris Y; Özgüroğlu, Mustafa; Ye, Dingwei; Feyerabend, Susan; Protheroe, Andrew; Sulur, Giri; Luna, Yesenia; Li, Susan; Mundle, Suneel; Chi, Kim N Journal: Lancet oncology Issue: Volume 20:Issue 5(2019) Page Start: 686 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. (18th March 2020) Authors: Suzuki, Hiroyoshi; Shin, Toshitaka; Fukasawa, Satoshi; Hashine, Katsuyoshi; Kitani, Sumiko; Ohtake, Noriyuki; Shibayama, Kazuhiro; Tran, Namphuong; Mundle, Suneel; Fizazi, Karim; Matsubara, Nobuaki Journal: Japanese journal of clinical oncology Issue: Volume 50:Number 7(2020) Page Start: 810 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. (February 2022) Authors: Baciarello, Giulia; Özgüroğlu, Mustafa; Mundle, Suneel; Leitz, Gerhard; Richarz, Ute; Hu, Peter; Feyerabend, Susan; Matsubara, Nobuaki; Chi, Kim N.; Fizazi, Karim Journal: European journal of cancer Issue: Volume 162(2022) Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study. (15th March 2022) Authors: Uemura, Hirotsugu; Arai, Gaku; Uemura, Hiroji; Suzuki, Hiroyoshi; Aoyama, Junya; Hatayama, Tomoyoshi; Ito, Miku; Lefresne, Florence; McCarthy, Sharon; Mundle, Suneel; He, Jin; Chi, Kim N Journal: International journal of urology Issue: Volume 29:Number 6(2022) Page Start: 533 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗